SCHEMBL5350659

SCHEMBL5350659

CC1CCCCN1NC(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.38
HSD11B1 P28845 1/20 0.38
EPHX2 P34913 1/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.34
LMNA P02545 1/20 0.34
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RECQL P46063 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5350664 1.00 AKR1C3 (0.38) AKR1C3HSD11B1EPHX2GAAHPGD
SCHEMBL5350661 1.00 AKR1C3 (0.38) AKR1C3HSD11B1EPHX2GAAHPGD
SCHEMBL6336369 0.77 ALDH1A1 (0.41) AKR1C3GAAHPGDALDH1A1KMT2A
SCHEMBL28543718 0.73 GAA (0.40) AKR1C3HSD11B1GAAHPGDALDH1A1
SCHEMBL28543678 0.73 GAA (0.40) AKR1C3HSD11B1GAAHPGDALDH1A1
SCHEMBL23581940 0.72 HPGD (0.37) AKR1C3GAAHPGDALDH1A1KMT2A
SCHEMBL11681085 0.72 SMN1; SMN2 (0.40) GAAHPGDALDH1A1KMT2AMEN1
SCHEMBL8343341 0.72 POLB (0.46) EPHX2ALDH1A1KMT2AMEN1PDK2
SCHEMBL8723669 0.71 HTT (0.39) AKR1C3GAAHPGDALDH1A1KMT2A
SCHEMBL10782714 0.71 HPGD (0.33) GAAHPGDALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-20040192926-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192926-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 AKR1C3 2568/4885HSD11B1 3606/4885EPHX2 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.